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This would suggest a score of two out of two against universities as
upholders of intellectual standards of honesty. It leaves the victim of
such theft very much in the cold.
Broom Lodge,
58 High Street,
Hemingford Grey,
Huntingdon PE189BN, UK J. M. WALSHE
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Storage of information by medical journals
SIR,-Like you in your Nov 17 editorial "Brevity in The Lancet"
we decided to "store, rather than print, the fine detail" of certain
articles which we call, in their published form, Technical Briefs. We
have published 5-10 in each monthly issue since 1986.
We have been surprised at the rarity of requests for these stored
details: among several hundred Technical Briefs published so far,
we have received only one such request. Of course, we do not know
the frequency with which authors are contacted directly by
interested readers.
Clinical Chemistry,
University of Virginia,
Charlottesville, VA 22908, USA
DAVID E. BRUNS,
Editor
Placental localisation in early pregnancy
SIR,&mdash;I disagree with the statement in your Feb 2 editorial that
"placental localisation at the initial scan cannot be recommended,
and when a low placenta is noted incidentally, it is not necessary
routinely to order a third-trimester scan".
Having been in practice as an obstetrician gynaecologist, and
specialising solely in prenatal diagnosis for the past 10 years, it is my
experience that the advent of new equipment certainly results in
better visualisation for sonograms done in the first and early second
trimester, especially with respect to the high instance of diagnosis of
low-lying placenta. I believe that the term placenta praevia is
inappropriate before 12 weeks’ gestation, unless placental tissue can
be clearly seen to cover the internal os region. It is regarded as
routine to always visualise the internal os and the whole
endocervical canal with an empty bladder to prevent any anatomical
distortions. Central placenta praevia can be diagnosed in early
pregnancy, especially when the relation of the placental tissue to the
os and the endocervical canal is noted. In my experience with these
cases, usually without any further abnormal bleeding, repeat
sonography between 16 and 18 weeks’ or as late as 20 weeks’
gestation, allows further confirmation of persistent praevia.
Prenatal diagnosis is routinely recommended for all women aged
35, when the incidence of chromosome abnormalities is 1 %. Surely
central placenta praevia with a population frequency of less than 1 %
or a delivery frequency of placenta praevia, which you cite as
anything from 2-3% to 169%, warrants a routine repeat sonogram
when in early pregnancy the placenta is seen to be overlying the os?
Koala Labs,
San Jose, Ca 95128, USA JOHN D. STEPHENS
Different hantavirus serotypes in western
Europe
SIR,&mdash;SO far, human infections with hantavirus, causing
haemorrhagic fever with renal syndrome (HFRS), other than those
transmitted by laboratory animals, have in western Europe been
associated with serotype III.1,2 The main reservoir host is the red
bank vole Clethrionomys glareolus. In the Netherlands we have
found serological evidence for serotype III in people who were
probably infected via contact with wild rodents.3 We have now
demonstrated this virus in animals. In lung extracts of four
seropositive red bank voles caught in an area of the Netherlands
where eight confirmed human cases of HFRS had been
documented, viral antigen was identified by ELISA. The ELISA
identified the virus as serotype III z
Antibody titres of human sera in ELISA, measured against
hantavirus serotype I. serotype III, and strain Dobrava.
(A) 11 sera from laboratory-associated cases and (B) 16 sera from
non-laboratory-associated cases in Netherlands and Belgium; and (C) 32
sera from non-laboratory-associated cases in Yugoslavia.
With the same ELISA system we have tested 32
immunofluorescent antibody positive sera, collected from people
with a non-laboratory-associated infection in Yugoslavia, against
serotype I (strain HV 76-118) which strongly cross-reacts with
serotype II (SR-11), serotype III (Hallnas), and a recent isolate
from Yugoslavia (strain Dobrava).’ The Dobrava strain was
isolated from the yellow-necked field mouse (Apodemus flavicollis)
during a recent period of high incidence of HFRS in Yugoslavia;4 it
reacted more strongly with sera specific for serotypes I and II than
with sera specific for serotype III. In addition 16 positive sera from
non-laboratory-associated infections and 11 positive sera from
laboratory-associated infections in the Netherlands and Belgium
were tested in the ELISA against these three viruses. All sera from
the laboratory-associated infections showed higher titres against
serotype I and strain Dobrava than against serotype III (figure, A).
The titres of these sera against serotype I were slightly higher than
those against strain Dobrava. All but 2 of the 16 sera from
non-laboratory-associated infections in the Netherlands and
Belgium showed the highest titres against hantavirus serotype III
(figure, B). 14 of the 32 sera from Yugoslavia showed the highest
titres against serotype I and strain Dobrava, whereas the other 18
reacted more strongly against serotype III (figure, C). This
confirms the results of an earlier serological study with an IFA,
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which indicated that two different hantavirus serotypes caused
HFRS in Yugoslavia.s
1 serum from the Netherlands and 1 from Belgium reacted more
strongly with serotype I and strain Dobrava than with serotype III.
Furthermore, both sera neutralised serotype I (strain HV 76-118)
in an 80% plaque reduction neutralisation assay, with titres of 10
and 40, respectively (Jim LeDuc, USAMRIID, Frederick, USA,
personal communication). Both individuals had recently been
infected and had not recently been abroad. In a report by Pilaski and
co-workers, 1 out of 21 sera from HFRS patients in Germany
proved to react more strongly with serotype 1.6 These data suggest
that in western Europe as in Yugoslavia non-laboratory-associated
hantavirus infections may be caused by more than one serotype.
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Increasing incidence of resistance among
shigellae to trimethoprim
SIR,&mdash;Shigella organisms resistant to trimethoprim (TMP) and
other antimicrobial agents have been reported,1,2 and this had led to
re-evaluation of the treatment regimen for shigellosis.
The first report ofTMP-resistant shigellae in Ontario, Canada,
appeared in 1980.3 Examination of isolates between 1977 and 1979
revealed 3% resistance to TMP among S sonnei and Sflexneri 2A
strains. As part of a long-term follow-up study of TMP resistance
among Shigella spp all isolates from stool samples received in our
diagnostic enteric laboratory at the Central Public Health
Laboratory, Ontario, Canada, between January and December,
1990, were examined for susceptibility to TMP and
sulphamethoxazole (SMX). Susceptibility was determined by the
agar dilution method with a Steers multiple replicator apparatus.4
Our results showed an increase in TMP resistance among
S sonnei isolates (12%) and a striking increase among strains of
Sflexneri--21% and 9% for Sflexneri 2A and 3A, respectively.
TMP resistance, not encountered in the previous study 3was found
among S dysenteriae type 1 strains; 6% of isolates were resistant. All
strains were highly resistant with minimum inhibitory
concentration (MIC) greater than 1000 &micro;g/ml. All isolates
also showed concomitant resistance to SMX with MIC above
512 &micro;g/ml, and resistance to co-trimoxazole (TMP/SMX
combination) with MIC more than 4/76 &micro;g/ml.
We were able to transfer resistance to both TMP and SMX from
all shigella isolates to Escherichia coliK-12 strain 711. The MICs of
TMP and SMX in the E coli transconjugants were much the same
(greater than 1000 Ilg/ml and 512 Ilg/ml, respectively) as those for
the shigella isolates. None of the isolates were resistant to the
fluoroquinolones ciprofloxacin and norfloxacin, which had MICs
of less than 1 J.1g/ml and less than 4 J.1g/ml, respectively.
The finding that a high percentage of strains in this study
transferred resistance to TMP and SMX emphasises the potential
for dissemination of these resistance factors to other strains. The
pattern observed also shows the need for prudent use of
antimicrobial agents in the treatment of shigellosis.
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Heparin and inflammatory bowel disease
SIR,&mdash;Mr Gaffney and colleagues (Jan 26, p 238) show a clinical
response to heparin in 3 patients with inflammatory bowel disease.
As they comment, thromboembolic complications are a recognised
feature of inflammatory bowel disease.’ I have managed 1 patient
with Crohn’s colitis and 2 with ulcerative colitis in whom venous
thrombosis and pulmonary emboli developed in conjunction with
active bowel disease, and none of whom improved while on heparin.
A 27-year-old man with a severe exacerbation of Crohn’s colitis
had an ileofemoral vein thrombisis complicated by multiple
pulmonary emboli. He was treated with intravenous heparin
40-50 000 U/day for one month in conjunction with systemic
corticosteroids and enteral nutrition, but despite this treatment his
condition deteriorated and he underwent colectomy.
I also question the wisdom of taking multiple endoscopic biopsy
specimens from patients on anticoagulants. The occlusive fibrinoid
ateriolar lesions reported in Crohn’s disease could be a consequence
of the inflammatory response rather than its cause .2
The history of inflammatory bowel disease is punctuated by case
reports of potential promising treatments. However, what is needed
are large controlled clinical trials to evaluate the efficacy of new and
established treatments. Despite the high prevalence of Crohn’s
disease and ulcerative colitis in Western countries such studies are
sadly lacking. Cardiologists have set the standard for clinical trials in
the 1990s that gastroenterologists should follow.
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Codon 178 mutation in ethnically diverse
Creutzfeldt-Jakob disease families
SIR,-We recently described a GAC-to-AAC mutation in codon
178 of the amyloid precursor gene in a Finnish family with
Creutzfeldt-Jakob disease (CJD).1 We now report that this same
mutation, which results in a substitution of asparagine for aspartic
acid in the encoded protein, is linked to transmissible CJD in
American families of Dutch and Hungarian descent, and in a
French family from Brittany.
The Dutch-American pedigree (family B in May and colleagues’
description,2 family MD in a review by Masters et al3) currently
includes 10 cases in three generations, 2 with transmission of disease
to non-human primates. The Hungarian-American kindred (ST)
now has 9 affected members in four generations, with 2 instances of
transmission. The French kindred (AB) has 3 affected members in
two generations, and 1 transmission. These patients have had
comparatively early onset of disease (mean 47 years, range 35-63)
and long duration of illness (mean 14 months, range 6-36);
however, they showed a characteristically broad array of clinical
manifestations, including dementia, signs of cerebellar, visual, and
